Comparative Pharmacology
Head-to-head clinical analysis: CORTALONE versus DIPROLENE AF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTALONE versus DIPROLENE AF.
CORTALONE vs DIPROLENE AF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response, and regulate metabolism.
Betamethasone dipropionate is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, thereby reducing the release of arachidonic acid and subsequent production of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
10-40 mg orally once daily in the morning; for acute exacerbations, up to 60 mg/day divided into 2-4 doses.
Apply a thin film to affected skin areas twice daily. Maximum 45 g per week. Not to exceed 2 consecutive weeks of treatment.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 2.5-3 hours (terminal half-life) for betamethasone dipropionate (active moiety); clinical effects persist beyond half-life due to receptor-mediated activity.
Primarily renal (60-70% as unchanged drug), with 10-20% biliary/fecal.
Primarily hepatic metabolism; inactive metabolites excreted renally (approximately 80-85% as metabolites in urine) and fecally (approximately 15-20%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid